VISTN — Vistin Pharma ASA Share Price
0.000.00%
Last trade - 00:00- NOK1.06bn
- NOK1.03bn
- NOK438.33m
- 88
- 40
- 77
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.28 | ||
| Price to Tang. Book | 3.28 | ||
| Price to Free Cashflow | 15.09 | ||
| Price to Sales | 2.42 | ||
| EV to EBITDA | 12.03 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.54% | ||
| Return on Equity | 15.31% | ||
| Operating Margin | 15.65% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 227.19 | 253.16 | 275.81 | 287.68 | 438.33 | n/a | n/a | 17.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Company’s customers are pharmaceutical companies worldwide.
Directors
- Ole Enger CHM (73)
- Kjell-Erik Nordby CEO (60)
- Alexander Karlsen CFO
- Vegard Heggem VOP
- Valborg Godal Vold VPR
- Hilde Hagen VPR (53)
- Bettina Banoun DRC
- Mimmi Berdal DRC
- Jorn-Henning Isaksen DRC
- Ase Musum DRC
- Finn Ruyter DRC (56)
- Oystein Spetalen DRC (55)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 24th, 2015
- Public Since
- June 10th, 2015
- No. of Employees
- 79
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 44,344,592
- Address
- Ostensjoveien 27, OSLO, 0661
- Web
- https://www.vistin.com/
- Phone
- +47 35984200
- Auditors
- Ernst & Young AS
Upcoming Events for VISTN
Vistin Pharma ASA Annual Shareholders Meeting
Vistin Pharma ASA Annual Shareholders Meeting
Dividend For VISTN.OL - 0.5000 NOK
Q2 2024 Vistin Pharma ASA Earnings Release
Similar to VISTN
Arctic Bioscience AS
Oslo Stock Exchange
Navamedic ASA
Oslo Stock Exchange
Photocure ASA
Oslo Stock Exchange
FAQ
What is the Vistin Pharma ASA share price?
As of Today at 19:24 UTC, shares in Vistin Pharma ASA are trading at NOK23.90. This share price information is delayed by 15 minutes.
How has the Vistin Pharma ASA share price performed this year?
Shares in Vistin Pharma ASA last closed at NOK23.90 and the price had moved by +23.51% over the past 365 days. In terms of relative price strength the Vistin Pharma ASA share price has outperformed the FTSE Global All Cap Index by +15.96% over the past year.
What are the analyst and broker recommendations for Vistin Pharma ASA?
The overall consensus recommendation for Vistin Pharma ASA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Vistin Pharma ASA dividend yield?
The Vistin Pharma ASA dividend yield is 4.18% based on the trailing twelve month period.
Does Vistin Pharma ASA pay a dividend?
Last year, Vistin Pharma ASA paid a total dividend of NOK1.00, and it currently has a trailing dividend yield of 4.18%.Looking ahead, shares in Vistin Pharma ASA are due to go ex-dividend on 2024-06-05 and the next dividend pay date is 2024-06-18.
When does Vistin Pharma ASA next pay dividends?
Vistin Pharma ASA are due to go ex-dividend on 2024-06-05 and the next dividend pay date is 2024-06-18. The historic dividend yield on Vistin Pharma ASA shares is currently 4.18%.
How do I buy Vistin Pharma ASA shares?
To buy shares in Vistin Pharma ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vistin Pharma ASA?
As of the previous close price of NOK23.90, shares in Vistin Pharma ASA had a market capitalisation of NOK1.06bn.
Where are Vistin Pharma ASA shares listed?
Here are the trading details for Vistin Pharma ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: VISTN
What kind of share is Vistin Pharma ASA?
Based on an overall assessment of its quality, value and momentum Vistin Pharma ASA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vistin Pharma ASA share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Vistin Pharma ASA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vistin Pharma ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -11.53%.
As of the last closing price of NOK23.90, shares in Vistin Pharma ASA were trading +3.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vistin Pharma ASA PE Ratio?
The Vistin Pharma ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK23.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vistin Pharma ASA?
Vistin Pharma ASA's management team is headed by:
- Ole Enger - CHM
- Kjell-Erik Nordby - CEO
- Alexander Karlsen - CFO
- Vegard Heggem - VOP
- Valborg Godal Vold - VPR
- Hilde Hagen - VPR
- Bettina Banoun - DRC
- Mimmi Berdal - DRC
- Jorn-Henning Isaksen - DRC
- Ase Musum - DRC
- Finn Ruyter - DRC
- Oystein Spetalen - DRC